Septerna Inc (SEPN)

Septerna topped expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 10, 2026, with revenue of $26.7 million topping the $19.2 million estimate, +39.1%, and EPS of -$0.29 topping the -$0.43 estimate by $0.14. Revenue rose 22375.6% to about $26.7 million (up from $119,000.00 a year ago), alongside gross profit of roughly $26.7 million, as the biotechnology company continues to advance its oral small molecule programs targeting G protein-coupled receptors across areas including endocrinology, immunology and inflammation, and metabolic disease. Profitability remained negative, with operating income of about -$16.8 million and operating margin at roughly -63%. Net income was about -$13.0 million, improving 47.5% from about -$24.8 million a year ago, while EPS improved 48.2% from -$0.56. Cash flow from operations was negative at roughly -$22.2 million. For the next period, consensus calls for EPS of -$0.41 on revenue of $20.8 million.